Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts

Trial Profile

Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2016

At a glance

  • Drugs Candida antigen (Primary)
  • Indications Warts
  • Focus Adverse reactions
  • Sponsors Nielsen BioSciences
  • Most Recent Events

    • 03 Oct 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016.
    • 21 Oct 2015 Planned end date changed from 1 Jun 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.
    • 21 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top